Why the study?
Hypertension is a prevalent complication of CKD and ABPM is the gold standard for diagnosis, but its usefulness and barriers to obtaining it needed assessment in pediatric patients.
Are there demographic barriers to obtaining ambulatory blood pressure monitoring in pediatric patients with chronic kidney disease?
Are there demographic barriers to obtaining ambulatory blood pressure monitoring in pediatric patients with chronic kidney disease?
ABPM is a useful tool for diagnosing and managing hypertension in pediatric CKD patients, with no specific demographic barriers identified for its utilization.
May support equitable ABPM access across demographics in pediatric CKD; hypothesis-generating pending prospective confirmation.
BACKGROUND: Hypertension is a prevalent complication of Chronic Kidney Disease (CKD) and Ambulatory Blood Pressure Monitoring (ABPM) is the gold standard for diagnosis. The aim of our study was to assess the usefulness of obtaining ABPM and to identify barriers to ABPM in this pediatric patient population. METHOD: In this retrospective analysis of patients with CKD stage 3-5 who were seen in one academic medical center's outpatient Pediatric Nephrology clinics between 2018 and 2021, we performed logistic regression to evaluate for associations between demographic factors and odds of having an ABPM. RESULT: Among 96 patients included in the study, 48 patients carried a diagnosis of hypertension. 31 patients had ABPM performed with usable data. In those who had ABPM done, 21 had normotension and 10 had undertreated hypertension. Our study also showed 1 had masked hypertension and 5 had white coat hypertension or effect. We did not find a statistically significant difference in those who did or did not undergo ABPM evaluation based on gender, previous diagnosis of hypertension, distance from clinic, language preference, or racial or ethnic identity. CONCLUSION: ABPM is a useful tool in our CKD population for the diagnosis and management of hypertension. We did not identify specific barriers to ABPM in our CKD population, and there were no differences in patients who obtained ABPM when looking at specific demographic and disease characteristics. Given these findings, we recommend focusing on areas of future improvement in spheres of patient and provider education as well as better quantification using surveys to further illuminate barriers.
No takes yet. Share an insight, caveat, or question.
Sadiq et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: